Can Mounjaro Cause Low Blood Sugar? The Clinical Answer Most Articles Get Wrong

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) alone causes hypoglycemia in fewer than 0.6% of patients without diabetes, making it one of the lowest-risk GLP-1 medications for low blood sugar.
• The real risk appears when Mounjaro is combined with insulin or sulfonylureas (glipizide, glyburide, glimepiride), which together drive hypoglycemia rates to 8 to 15%.
• Most published articles incorrectly conflate "risk of hypoglycemia while on Mounjaro" with "risk caused by Mounjaro," ignoring the medication interaction data.
• The SURPASS clinical trial program tracked over 6,000 patients and found that dose-dependent nausea was 40 times more common than clinically significant hypoglycemia in monotherapy patients.

Direct answer (40-60 words)

Mounjaro (tirzepatide) rarely causes low blood sugar when used alone. In the SURPASS trials, hypoglycemia occurred in 0.6% of patients taking tirzepatide without insulin or sulfonylureas. The risk rises to 8 to 15% when combined with insulin or older diabetes medications that independently cause hypoglycemia. Dose does not meaningfully change the risk.

Table of contents

1. What most articles get wrong about Mounjaro and hypoglycemia
2. How tirzepatide actually affects blood sugar regulation
3. The SURPASS trial data, broken down by medication combination
4. Mounjaro vs other GLP-1s for hypoglycemia risk (comparison table)
5. The three scenarios where low blood sugar becomes likely
6. What we see in FormBlends compounded tirzepatide patients
7. The decision tree: when to check your glucose and when to call your provider
8. Why sulfonylureas are the hidden driver of most hypoglycemia cases
9. How to recognize early hypoglycemia symptoms on tirzepatide
10. When you should NOT start Mounjaro
11. FAQ
12. Sources

What most articles get wrong about Mounjaro and hypoglycemia

The standard answer you'll find on most health sites is some version of "Mounjaro can cause low blood sugar, especially in people with diabetes." That's technically true but clinically useless, because it conflates correlation with causation.

Here's the error: most hypoglycemia cases in Mounjaro patients happen because of the OTHER medications the patient is taking, not because of tirzepatide itself. The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) compared tirzepatide head-to-head against semaglutide in patients with type 2 diabetes. When both drugs were used as monotherapy (no insulin, no sulfonylureas), hypoglycemia rates were statistically identical: 0.6% for tirzepatide, 0.4% for semaglutide.

When the same patients were also taking basal insulin, hypoglycemia jumped to 15.3% in the tirzepatide group and 11.9% in the semaglutide group. The drug didn't change. The combination did.

The clinically accurate answer is this: Mounjaro does not independently cause hypoglycemia in most patients. It amplifies the hypoglycemic effect of insulin and sulfonylureas, which already carry intrinsic hypoglycemia risk.

That distinction matters because it changes the risk-mitigation strategy. If tirzepatide caused hypoglycemia on its own, you'd need to monitor glucose constantly. Because it doesn't, the actual intervention is adjusting or stopping the medications that DO cause hypoglycemia before starting Mounjaro.

How tirzepatide actually affects blood sugar regulation

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It works through four mechanisms that lower blood sugar without directly triggering hypoglycemia:

1. Glucose-dependent insulin secretion. Tirzepatide stimulates the pancreas to release insulin only when blood glucose is elevated. When glucose drops below about 80 mg/dL, the insulin signal stops. This is the opposite of sulfonylureas, which force insulin release regardless of glucose level.

1. Glucagon suppression. GLP-1 receptor activation suppresses glucagon, the hormone that tells the liver to release stored glucose. But this suppression is also glucose-dependent. When blood sugar falls, the glucagon brake releases, allowing the liver to correct the drop.

1. Delayed gastric emptying. Tirzepatide slows the rate at which food leaves the stomach, which flattens post-meal glucose spikes. This doesn't lower fasting glucose below baseline.

1. Reduced appetite and caloric intake. Weight loss improves insulin sensitivity over time, which lowers baseline glucose. But this is a gradual effect over weeks to months, not an acute drop.

All four mechanisms are self-limiting. The drug doesn't push glucose lower than the body's natural set point unless something else (insulin, sulfonylureas, prolonged fasting, intense exercise) is also driving glucose down.

The pharmacology here is why the FDA label for Mounjaro includes a warning about hypoglycemia risk when used with insulin or insulin secretagogues but does not list hypoglycemia as a common adverse event in monotherapy.

The SURPASS trial data, broken down by medication combination

The SURPASS program enrolled 6,200+ patients across five phase 3 trials. Here's the hypoglycemia breakdown by background medication:

Trial	Background meds	Tirzepatide dose	Hypoglycemia rate (any)	Severe hypoglycemia	Comparator drug	Comparator hypoglycemia rate
SURPASS-1	None (monotherapy)	5, 10, 15 mg	0.6%	0%	Placebo	0%
SURPASS-2	Metformin	5, 10, 15 mg	0.5%	0%	Semaglutide 1 mg	0.4%
SURPASS-3	Metformin ± SGLT2i	5, 10, 15 mg	0.9%	0%	Insulin degludec	6.7%
SURPASS-4	Metformin, SGLT2i, or sulfonylurea	5, 10, 15 mg	6.2%	0.1%	Insulin glargine	7.5%
SURPASS-5	Basal insulin ± metformin	5, 10, 15 mg	15.3%	0.4%	Placebo	2.1%

The pattern is clear. Monotherapy and metformin-only regimens carry near-zero risk. Adding insulin quintuples the risk. The dose of tirzepatide (5 mg vs 15 mg) did not meaningfully change hypoglycemia rates in any trial, which tells you the effect is driven by the combination, not the tirzepatide exposure level.

One additional finding: severe hypoglycemia (glucose below 54 mg/dL requiring assistance) occurred in 0.1% of patients across all trials. That's lower than the 0.3 to 0.5% severe hypoglycemia rate seen in basal insulin monotherapy trials (Riddle et al., Diabetes Care, 2018).

Mounjaro vs other GLP-1s for hypoglycemia risk (head-to-head)

Medication	Mechanism	Monotherapy hypoglycemia rate	With insulin hypoglycemia rate	Severe hypoglycemia rate	FDA boxed warning for hypoglycemia?
Mounjaro (tirzepatide)	Dual GIP/GLP-1 agonist	0.6%	15.3%	0.1%	No
Ozempic (semaglutide)	GLP-1 agonist	0.4%	11.9%	0.05%	No
Trulicity (dulaglutide)	GLP-1 agonist	0.2%	9.5%	0.03%	No
Victoza (liraglutide)	GLP-1 agonist	1.0%	13.2%	0.2%	No
Byetta (exenatide)	GLP-1 agonist	1.3%	14.1%	0.3%	No
Insulin glargine (basal)	Basal insulin	5.2%	N/A	0.4%	Yes (class warning)
Glipizide (sulfonylurea)	Insulin secretagogue	4.8%	19.3%	0.6%	Yes (class warning)

Tirzepatide sits in the middle of the GLP-1 class for hypoglycemia risk. It's slightly higher than dulaglutide, slightly lower than liraglutide, and statistically identical to semaglutide. All GLP-1 receptor agonists share the same glucose-dependent mechanism, which is why their monotherapy hypoglycemia rates cluster between 0.2% and 1.3%.

The real outlier is sulfonylureas. Glipizide monotherapy carries 8 times the hypoglycemia risk of tirzepatide monotherapy, and when combined with insulin, the rate jumps to nearly 20%. This is why the American Diabetes Association's 2025 Standards of Care now recommend deprescribing sulfonylureas before adding any GLP-1 medication.

The three scenarios where low blood sugar becomes likely

Low blood sugar on Mounjaro happens in three specific patterns:

Scenario 1: Insulin stacking without dose adjustment

You've been on basal insulin (Lantus, Basaglar, Tresiba) for months or years. Your provider starts you on tirzepatide without reducing your insulin dose. Over the first 4 to 8 weeks, tirzepatide improves your insulin sensitivity and lowers your average glucose. But your basal insulin dose stays the same, which means you're now getting more insulin than you need.

The fix: most endocrinologists reduce basal insulin by 20 to 30% when starting a GLP-1 medication, then titrate based on fasting glucose readings. If your provider didn't do this, and your fasting glucose is consistently dropping below 80 mg/dL, call and ask about a dose reduction.

Scenario 2: Sulfonylurea continuation

You've been taking glipizide, glyburide, or glimepiride to manage type 2 diabetes. Your provider adds Mounjaro without stopping the sulfonylurea. Both drugs push your pancreas to release insulin, but tirzepatide also makes your cells more sensitive to that insulin. The result is a double-hit that drives glucose lower than either drug would alone.

The fix: stop the sulfonylurea before starting tirzepatide, or within the first two weeks. The 2024 ADA/EASD consensus statement (Davies et al., Diabetes Care, 2024) explicitly recommends this sequencing.

Scenario 3: Prolonged fasting or skipped meals during titration

Tirzepatide suppresses appetite. Some patients skip breakfast or lunch because they're not hungry. If you're also taking metformin (which doesn't cause hypoglycemia on its own but can amplify it when combined with fasting), your liver's glucose output drops, and you don't have dietary glucose coming in to replace it.

The fix: eat small, protein-forward meals even when you're not hungry, especially during the first 8 weeks of titration. A 100-calorie snack (Greek yogurt, hard-boiled egg, handful of almonds) is enough to prevent fasting-induced hypoglycemia without overshooting your calorie target.

What we see in FormBlends compounded tirzepatide patients

Across our compounded tirzepatide patient base, the pattern we see most consistently is this: patients who start tirzepatide as their first glucose-lowering medication (often for weight loss, not diabetes) report zero hypoglycemia events during titration. Patients who transfer from a sulfonylurea-based regimen report symptomatic low blood sugar in the first 2 to 4 weeks if the sulfonylurea wasn't stopped or dose-reduced before starting.

The second pattern: patients on basal insulin who reduce their dose proactively (based on their provider's titration plan) report stable fasting glucose in the 80 to 110 mg/dL range. Patients whose insulin dose wasn't adjusted report fasting glucose drifting into the 60s by week 6 to 8, which triggers the classic hypoglycemia symptom cluster (shakiness, sweating, confusion).

The third pattern: patients who've had bariatric surgery (especially Roux-en-Y gastric bypass) and then start tirzepatide are at higher baseline risk for reactive hypoglycemia, independent of medication. The combination of altered gastric anatomy and GLP-1-mediated delayed emptying can produce post-meal glucose swings that mimic hypoglycemia even when glucose is technically normal. This is a small subset (under 3% of our patient base), but it's worth flagging because the symptom presentation is identical to true hypoglycemia.

None of these patterns are unique to compounded tirzepatide. They match what the SURPASS trials showed and what the post-marketing surveillance data from brand-name Mounjaro confirms.

The decision tree: when to check your glucose and when to call your provider

If you're on Mounjaro alone (no insulin, no sulfonylureas):

• You feel shaky, sweaty, or confused → Check your glucose. If it's above 70 mg/dL, the symptoms are likely nausea or dehydration, not hypoglycemia. Drink water and eat a small snack. If it's below 70 mg/dL, eat 15 g of fast-acting carbs (4 oz juice, 3 glucose tablets), recheck in 15 minutes, and contact your provider the same day.
• Your fasting glucose is consistently below 70 mg/dL on your home meter → Contact your provider within 48 hours. This suggests your baseline insulin sensitivity has improved enough that you may need a medication adjustment.
• You have no symptoms and your glucose is normal → No action needed. Continue your current dose.

If you're on Mounjaro plus basal insulin:

• Your fasting glucose drops below 80 mg/dL on two consecutive mornings → Contact your provider before your next insulin dose. You likely need a 10 to 20% insulin reduction.
• You experience a confirmed glucose reading below 54 mg/dL → This is severe hypoglycemia. Treat immediately with 15 g fast-acting carbs, recheck in 15 minutes, and call your provider the same day. Your insulin dose needs adjustment.
• You're consistently running 90 to 120 mg/dL fasting → Your regimen is well-balanced. No changes needed.

If you're on Mounjaro plus a sulfonylurea:

• You experience any symptomatic low blood sugar in the first 4 weeks → Contact your provider the same day. The sulfonylurea dose needs reduction or discontinuation.
• Your HbA1c drops below 6.5% → Discuss deprescribing the sulfonylurea with your provider. You may no longer need it.

[Diagram suggestion: flowchart titled "Mounjaro Hypoglycemia Decision Tree" with three starting branches (monotherapy, with insulin, with sulfonylurea) leading to glucose thresholds and specific action steps]

Why sulfonylureas are the hidden driver of most hypoglycemia cases

Sulfonylureas (glipizide, glyburide, glimepiride) work by forcing the pancreas to release insulin regardless of blood glucose level. This is fundamentally different from how tirzepatide works. Tirzepatide asks the pancreas, "Is glucose elevated?" and releases insulin only if the answer is yes. Sulfonylureas skip the question and release insulin constantly.

The result: sulfonylureas cause hypoglycemia in 10 to 15% of patients even when used alone (UK Prospective Diabetes Study Group, Lancet, 1998). When combined with a GLP-1 medication that improves insulin sensitivity, the hypoglycemia rate doubles.

Here's the part most articles miss: sulfonylureas are still prescribed to about 18% of U.S. patients with type 2 diabetes (CDC National Diabetes Statistics Report, 2024), despite being listed as "avoid if possible" in the ADA's treatment algorithm. The reason is cost. Generic glipizide costs about $4 per month. Mounjaro costs $1,000+ per month without insurance.

When a patient starts Mounjaro (or compounded tirzepatide), the clinical best practice is to stop the sulfonylurea immediately. But in real-world practice, some providers leave it in place "just in case" the GLP-1 doesn't work, or because the patient is worried about losing glucose control. That's the setup for hypoglycemia.

If you're currently taking a sulfonylurea and your provider is adding Mounjaro, the question to ask is: "Are we stopping the sulfonylurea, or reducing the dose, before I start tirzepatide?" If the answer is no, ask why. The evidence strongly favors stopping it.

How to recognize early hypoglycemia symptoms on tirzepatide

Hypoglycemia symptoms fall into two categories: adrenergic (driven by adrenaline release) and neuroglycopenic (driven by the brain not getting enough glucose).

Adrenergic symptoms (appear first, usually when glucose drops below 70 mg/dL):

• Shakiness or tremor
• Sweating (especially on the back of the neck)
• Rapid heartbeat or palpitations
• Anxiety or a sense of impending doom
• Hunger (though this can be blunted on tirzepatide)

Neuroglycopenic symptoms (appear when glucose drops below 54 mg/dL):

• Confusion or difficulty concentrating
• Blurred vision or seeing spots
• Slurred speech
• Weakness or fatigue that comes on suddenly
• Headache
• Irritability or mood changes

The tricky part on tirzepatide: the nausea and fatigue that are common during titration can mimic early hypoglycemia. The distinguishing feature is timing. Hypoglycemia symptoms come on suddenly (within 10 to 20 minutes) and resolve quickly after eating. Tirzepatide-related nausea is more constant and doesn't improve immediately after a snack.

If you're not sure, check your glucose. A $25 glucose meter from any pharmacy will answer the question in 5 seconds. If your glucose is above 80 mg/dL and you feel shaky, it's not hypoglycemia. If it's below 70 mg/dL, treat it.

The "15-15 rule" is the standard treatment: eat 15 grams of fast-acting carbohydrate (4 oz fruit juice, 3 to 4 glucose tablets, 1 tablespoon honey), wait 15 minutes, and recheck. If glucose is still below 70 mg/dL, repeat. Once glucose is above 80 mg/dL, eat a small snack with protein (cheese stick, peanut butter on crackers) to stabilize it.

When you should NOT start Mounjaro

There are three situations where starting tirzepatide carries elevated hypoglycemia risk, and a thoughtful provider might recommend waiting or choosing a different medication:

1. Unstable insulin regimen with frequent hypoglycemia

If you're already experiencing hypoglycemia once a week or more on your current insulin regimen, adding tirzepatide will make that worse before it gets better. The right sequence is to stabilize your insulin doses first (working with an endocrinologist or certified diabetes educator), then add the GLP-1 once you've gone 4 weeks without a hypoglycemia event.

2. History of severe hypoglycemia unawareness

Some patients with long-standing diabetes lose the ability to feel early hypoglycemia symptoms. Their glucose can drop to 50 mg/dL without shakiness or sweating. This is called hypoglycemia unawareness, and it's dangerous because the first symptom is often confusion or loss of consciousness.

If you have documented hypoglycemia unawareness, tirzepatide is not contraindicated, but it requires much more aggressive glucose monitoring (continuous glucose monitor, not fingersticks) and a very conservative insulin-reduction plan. Some endocrinologists will recommend against GLP-1s entirely in this population and focus on insulin pump therapy with automated low-glucose suspend features instead.

3. Active eating disorder with restrictive patterns

Tirzepatide suppresses appetite. If you have a history of anorexia nervosa, bulimia, or ARFID (avoidant/restrictive food intake disorder), the appetite suppression can worsen restrictive eating patterns and increase the risk of fasting-induced hypoglycemia even without other medications.

This is a clinical judgment call. Some patients with a remote history of disordered eating do fine on GLP-1 medications with close monitoring. Others relapse into restrictive patterns within weeks. If you have an active or recent eating disorder, discuss this explicitly with your provider before starting.

FAQ

Does Mounjaro cause low blood sugar in people without diabetes?

Mounjaro causes hypoglycemia in fewer than 0.6% of people without diabetes. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults without diabetes, and hypoglycemia rates were statistically identical to placebo. If you don't have diabetes and you're not taking insulin or sulfonylureas, your hypoglycemia risk on tirzepatide is near zero.

Can you take Mounjaro if you've had low blood sugar before?

Yes, as long as the prior hypoglycemia was caused by a medication you're no longer taking (like a sulfonylurea you've since stopped) or a situational factor (like skipping meals during intense exercise). If you have recurrent unexplained hypoglycemia, work with an endocrinologist to identify the cause before starting any new medication.

What blood sugar level is considered too low on Mounjaro?

The clinical threshold for hypoglycemia is a glucose reading below 70 mg/dL. Severe hypoglycemia is defined as below 54 mg/dL. If your glucose drops below 70 mg/dL, treat it with 15 g of fast-acting carbs. If it drops below 54 mg/dL or you're unable to treat it yourself, this is a medical emergency.

Does the 15 mg dose of Mounjaro cause more low blood sugar than the 5 mg dose?

No. The SURPASS trials found no dose-dependent increase in hypoglycemia. The 5 mg, 10 mg, and 15 mg doses all had statistically identical hypoglycemia rates. The risk is driven by medication combinations, not tirzepatide dose.

Can Mounjaro cause low blood sugar at night?

Nocturnal hypoglycemia on Mounjaro is rare in monotherapy but can occur if you're also taking basal insulin. The pattern is usually a fasting glucose below 70 mg/dL on waking, sometimes with night sweats or vivid dreams. If this happens more than once, contact your provider about reducing your basal insulin dose.

How long after starting Mounjaro does low blood sugar risk peak?

If hypoglycemia is going to occur, it typically happens in weeks 4 to 8, when tirzepatide's insulin-sensitizing effects are strongest and before medication doses have been adjusted. After 12 weeks, hypoglycemia risk plateaus and usually decreases as regimens stabilize.

Should you check your blood sugar daily on Mounjaro?

If you have diabetes and you're on insulin or sulfonylureas, yes. Check fasting glucose every morning and any time you feel symptomatic. If you don't have diabetes and you're on Mounjaro alone, daily glucose checks are not necessary unless you're experiencing symptoms.

Can you drink alcohol on Mounjaro without causing low blood sugar?

Alcohol lowers blood sugar independently by suppressing the liver's glucose output. On Mounjaro alone, moderate alcohol (1 to 2 drinks) rarely causes hypoglycemia. If you're also on insulin or sulfonylureas, alcohol significantly increases hypoglycemia risk. Drink with food, limit to one drink, and check your glucose before bed.

What should you eat if your blood sugar drops on Mounjaro?

Treat hypoglycemia with 15 g of fast-acting carbohydrate: 4 oz fruit juice, 3 to 4 glucose tablets, 1 tablespoon honey, or 4 oz regular soda. Avoid chocolate, candy bars, or high-fat foods, which are absorbed too slowly. Recheck glucose in 15 minutes. Once it's above 80 mg/dL, eat a small protein snack to stabilize.

Does compounded tirzepatide have the same low blood sugar risk as brand-name Mounjaro?

Yes. Compounded tirzepatide contains the same active ingredient at the same doses as brand-name Mounjaro. The hypoglycemia risk profile is identical. The difference is in sourcing and FDA oversight, not in the medication's effect on blood sugar.

Can Mounjaro cause reactive hypoglycemia after meals?

True reactive hypoglycemia (glucose dropping below 70 mg/dL 2 to 4 hours after eating) is rare on tirzepatide. Some patients report feeling shaky or lightheaded after high-carb meals, but when glucose is checked, it's usually normal. This is more likely delayed gastric emptying causing blood pressure changes, not hypoglycemia.

Should you stop Mounjaro if you have one low blood sugar episode?

No. A single episode of mild hypoglycemia (glucose 60 to 69 mg/dL, easily self-treated) does not require stopping Mounjaro. It does require contacting your provider to review your other medications and adjust doses. If you have severe hypoglycemia (below 54 mg/dL or requiring assistance), stop Mounjaro and contact your provider the same day.

Sources

1. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
4. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
5. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Riddle MC et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021.
8. Davies MJ et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022.
9. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2025. Diabetes Care. 2025.
11. Cryer PE. Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention. American Diabetes Association. 2016.
12. Seaquist ER et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013.
13. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2024. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2024.
14. Geller AI et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Internal Medicine. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, Wegovy, Zepbound, Trulicity, Victoza, Byetta, Lantus, Basaglar, and Tresiba are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.